Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT00070564 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

S0221 Adjuvant Doxorubicin, Cyclophosphamide, and Paclitaxel in Treating Patients With Breast Cancer

StatusActive, Not Recruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

The 50 most recent of 824 record versions are accounted for below. See every version on ClinicalTrials.gov ↗

  1. 9 versions Re-verified since Dec 3, 2018, no change to tracked fieldsv816-v824
  2. Secondary endpoints: details revised at 1 of 7 entries Site details revised at 1 of 542 sitesv815 Show 1 more changeShow less
    • Site details revised at 1 of 542 sites
  3. Results first posted: Apr 17, 2017 Primary endpoints: 3 to 2 · Enrollment target: estimated 3250 to confirmed 3294 · Primary completion date changed from estimate of Feb 2017 to Jan 2015 · 2 morev814 Show 5 more changesShow less
    • Primary endpoints: 3 to 2
    • Enrollment target: estimated 3250 to confirmed 3294
    • Primary completion date changed from estimate of Feb 2017 to Jan 2015
    • Completion date: Feb 2017 to Jan 2027
    • Secondary endpoints: 2 to 7

    See this version in full on ClinicalTrials.gov ↗

  4. 2 versions Re-verified since Aug 19, 2014, no change to tracked fieldsv812-v813
  5. Completion date: Feb 2017 Secondary endpoints: details revised at 2 of 2 entries · Study title expanded, about 1 wordv811 Show 2 more changesShow less
    • Secondary endpoints: details revised at 2 of 2 entries
    • Study title expanded, about 1 word

    See this version in full on ClinicalTrials.gov ↗

Show 36 earlier versionsHide 36 earlier versions
  1. Primary completion date: Jun 2012 to Feb 2017v810
  2. Trial status: Recruiting to Active, Not Recruiting Study sites: 543 to 542v809 Show 1 more changeShow less
    • Study sites: 543 to 542
  3. Study sites: 544 to 543v808
  4. Study sites: 545 to 544v807
  5. Study sites: 544 to 545v806
  6. Study sites: 533 to 544v805
  7. Study sites: 532 to 533v804
  8. Study sites: 541 to 532v803
  9. Study sites: 535 to 541v802
  10. Study sites: 534 to 535v801
  11. Study sites revised (534)v800 See this version in full on ClinicalTrials.gov ↗
  12. Study sites: 552 to 534v799
  13. Study sites: 551 to 552v798
  14. Site details revised at 2 of 551 sitesv797
  15. Study sites: 548 to 551v796
  16. Study sites: 553 to 548v795
  17. Study sites revised (553)v794 See this version in full on ClinicalTrials.gov ↗
  18. Study sites: 550 to 553v793
  19. Study sites: 546 to 550v792
  20. Study sites: 545 to 546v791
  21. Study sites revised (545)v790 See this version in full on ClinicalTrials.gov ↗
  22. Study sites: 546 to 545v789
  23. Study sites: 547 to 546v788
  24. Study sites revised (547)v787 See this version in full on ClinicalTrials.gov ↗
  25. Study sites revised (547)v786 See this version in full on ClinicalTrials.gov ↗
  26. Study sites: 548 to 547v785
  27. Study sites: 547 to 548v784
  28. Study sites: 548 to 547v783
  29. Study sites: 549 to 548v782
  30. Study sites: 548 to 549v781
  31. Site details revised at 1 of 548 sitesv780
  32. Study sites: 549 to 548v779
  33. Study sites: 552 to 549v778
  34. Site contacts updated at 6 of 552 sitesv777
  35. Study sites: 551 to 552v776
  36. Site contacts updated at 2 of 551 sitesv775
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
RATIONALE: Drugs used in chemotherapy, such as doxorubicin, cyclophosphamide, and paclitaxel, use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug and giving them after surgery may kill any remaining tumor cells. It is not yet known which combination chemotherapy regimen is more effective in treating resected breast cancer. PURPOSE: This randomized phase III trial is comparing 2 different regimens of combination chemotherapy to see how well they work in treating patients who have undergone surgery for stage I, stage II, or stage III breast cancer.
Trial Details
NCT Number NCT00070564
Lead Sponsor SWOG Cancer Research Network
Collaborators: National Cancer Institute (NCI)
Conditions Breast Cancer
Enrollment 3,294 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov